{"id":"W2463180023","doi":"10.1080/14712598.2016.1205582","title":"Ustekinumab: a novel therapeutic option in Crohn’s disease","year":2016,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Ustekinumab; Medicine; Crohn's disease; Disease; Expert opinion; Vedolizumab; Monoclonal; Tumor necrosis factor alpha; Intensive care medicine; Monoclonal antibody; Immunology; Internal medicine; Infliximab; Antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002705817,0.0006908179,0.0007875066,0.0001444869,0.00008061773,0.00003958318,0.0005653335,0.0007833671,0.0001958663],"category_scores_gemma":[0.00008506075,0.0004028984,0.0006975695,0.0001213751,0.0001698147,0.000005631309,0.0001135537,0.0002428502,0.000176518],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001085419,"about_ca_system_score_gemma":0.0002256159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00000167402,"about_ca_topic_score_gemma":4.819153e-7,"domain_scores_codex":[0.9971588,0.0005059825,0.0006043247,0.001039091,0.0002001388,0.0004916972],"domain_scores_gemma":[0.9985631,0.00007000189,0.000256834,0.000810507,0.0000467073,0.0002528271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001066055,0.0004676914,0.00004571305,0.00008064257,0.00010215,0.00005549584,0.0000104585,0.000001083383,0.0004352696,0.001021521,0.0003686471,0.9963453],"study_design_scores_gemma":[0.00105559,0.000221823,0.00314151,0.001732136,0.00000112112,0.000005599389,0.000004224269,0.000001960899,0.0000125366,0.0000997449,0.9930994,0.0006243541],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004757174,0.9968432,0.0002466546,0.00007230592,0.0007268689,0.00128096,0.0001311332,0.00005010613,0.000173092],"genre_scores_gemma":[0.0007227198,0.9953721,0.00005004645,0.001043867,0.001171464,0.0008584054,0.0006268269,0.0000785685,0.00007602385],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9957209,"threshold_uncertainty_score":0.9998423,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1118643839363814,"score_gpt":0.380050036030723,"score_spread":0.2681856520943416,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}